Business
Appointment of Chief Executive Officer
Appointment of Chief Executive Officer.
About this update from Theracryf Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9223Z\n Evgen Pharma PLC\n 24 September 2020\n \n \n \n \n Evgen Pharma Plc\n \n \n (\"Evgen\" or \"the Company\")\n \n \n \n \n \n Appointment of Chief Executive Officer\n \n \n \n \n \n Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and other conditions, announces that Huw Jones PhD will be joining the Board as Chief Executive Officer in early October.\n \n \n \n \n \n Dr Jones has over 30 years' experience of leadership roles in public and private R&D-based companies within the biotechnology and pharmaceutical sector, with a particular focus on pre-clinical and clinical drug development, dilutive and non-dilutive financing and business development. He is Chairman of Chronos Therapeutics Ltd, Non-Executive Director of Rexgenero Ltd and Strategic Advisor to Gen2 Neuroscience Ltd. Dr Jones holds a PhD in pharmacology from the University of Birmingham, UK.\n \n \n \n \n \n \n Barry Clare, Chairman of Evgen commented: \n \n \n \"The Board is delighted to appoint Huw as our new CEO as we work together to deliver the undoubted potential of SFX-01. We believe that SFX-01 has significant value across a range of diseases including cancer and respiratory diseases such as \n \n COVID-19\n \n .\"\n \n \n \n \n \n \n \n Commenting on his appointment, Huw Jones said\n \n : \"I am honoured to join the Board of Evgen at such an exciting time and to working with Board colleagues, management and partners to realise the promise of SFX-01. I've been impressed by the focus and commitment of my new colleagues and look forward to working with them towards providing a new treatment for patients with high unmet medical needs.\"\n \n \n \n \n \n The following information regarding the appointment of Dr Huw Jones (aged 60) is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies:\n \n \n \n \n \n \n \n \n Current directorships and/or partnerships\n \n \n \n \n \n \n \n \n \n \n \n \n \n Daffodil Consulting LLP\n \n \n \n \n \n \n \n \n \n \n \n \n \n Chronos Therapeutics Limited\n \n \n \n \n \n \n \n \n \n \n \n \n \n Rexgenero Limited\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n In accordance with Schedule 2(g) v, Dr Jones was CEO of Ardana Plc at the time of its adm...